<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.113177</article-id><article-id pub-id-type="publisher-id">ACM-41209</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210300000_24920844.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  子宫平滑肌肉瘤恶性潜能预测：CT与临床病理特征相关性研究
  Prediction of Malignant Potential of Leiomyosarcoma: Correlation between Preoperative CT and Pathological Features
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>康</surname><given-names>巍</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>黄</surname><given-names>向阳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>钟</surname><given-names>武宁</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>广西医科大学附属肿瘤医院影像中心，广西 南宁</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff3"><addr-line>广西医科大学附属肿瘤医院化疗五科，广西 南宁</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>1228</fpage><lpage>1234</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：分析子宫平滑肌肉瘤(uLMS) CT增强强化程度与Ki-67增值指数是否具有相关性。方法：回顾性分析14例uLMS的临床表现、CT特点、肿瘤标志物及病理特点，所有病例均经过病理证实。本文分析uLMS CT增强强化程度与Ki-67增值指数的相关性。结果：uLMS实性成分CT呈中度至明显强化，且与Ki67增殖指数具有明显的相关性(p &lt; 0.05)。另外，大部分病人CA125值明显升高，且Desmin及SMA表达阳性。结论：对于uLMS CT强化程度及Ki67增值情况可能可以预测其恶性转化过程，CA125升高也能预测uLMS的恶性程度。
    Objective: To analyze the correlation between the degree of enhancement of leiomyosarcoma CT and Ki-67 value-added index. Methods: The clinical manifestations, CT features, tumor markers and pathological features of 14 cases of uLMS were analyzed retrospectively. All cases were confirmed by pathology. The correlation between the enhancement degree of uLMS CT and the value-added index of Ki-67 was analyzed. Results: The solid components of uLMS showed moderate to significant enhancement on CT, and there was a significant correlation between them and Ki-67 proliferation index (p &lt; 0.05). In addition, CA125 was significantly elevated in most patients, and Desmin and SMA were positive. Conclusion: The enhancement of CT and the increase of Ki-67 may predict the malignant transformation of uLMS, and the increase of CA125 may also predict the malignant degree of uLMS. 
  
 
</p></abstract><kwd-group><kwd>子宫平滑肌肉瘤，CT，组织病理学, Uteruses Leiomyosarcomas</kwd><kwd> Computed Tomography</kwd><kwd> Histopathology</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：分析子宫平滑肌肉瘤(uLMS) CT增强强化程度与Ki-67增值指数是否具有相关性。方法：回顾性分析14例uLMS的临床表现、CT特点、肿瘤标志物及病理特点，所有病例均经过病理证实。本文分析uLMS CT增强强化程度与Ki-67增值指数的相关性。结果：uLMS实性成分CT呈中度至明显强化，且与Ki67增殖指数具有明显的相关性(p &lt; 0.05)。另外，大部分病人CA125值明显升高，且Desmin及SMA表达阳性。结论：对于uLMS CT强化程度及Ki67增值情况可能可以预测其恶性转化过程，CA125升高也能预测uLMS的恶性程度。</p></sec><sec id="s2"><title>关键词</title><p>子宫平滑肌肉瘤，CT，组织病理学</p></sec><sec id="s3"><title>Prediction of Malignant Potential of Leiomyosarcoma: Correlation between Preoperative CT and Pathological Features</title><p>Wei Kang<sup>1</sup>, Xiangyang Huang<sup>1*</sup>, Wuning Zhong<sup>2*</sup></p><p><sup>1</sup>Department of Radiology, Guangxi Medical University Cancer Hospital, Nanning Guangxi</p><p><sup>2</sup>Department of the Fifth Chemotherapy, Guangxi Medical University Cancer Hospital, Nanning Guangxi</p><p><img src="//html.hanspub.org/file/60-1571968x4_hanspub.png" /></p><p>Received: Feb. 17<sup>th</sup>, 2021; accepted: Mar. 5<sup>th</sup>, 2021; published: Mar. 25<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/60-1571968x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To analyze the correlation between the degree of enhancement of leiomyosarcoma CT and Ki-67 value-added index. Methods: The clinical manifestations, CT features, tumor markers and pathological features of 14 cases of uLMS were analyzed retrospectively. All cases were confirmed by pathology. The correlation between the enhancement degree of uLMS CT and the value-added index of Ki-67 was analyzed. Results: The solid components of uLMS showed moderate to significant enhancement on CT, and there was a significant correlation between them and Ki-67 proliferation index (p &lt; 0.05). In addition, CA125 was significantly elevated in most patients, and Desmin and SMA were positive. Conclusion: The enhancement of CT and the increase of Ki-67 may predict the malignant transformation of uLMS, and the increase of CA125 may also predict the malignant degree of uLMS.</p><p>Keywords:Uteruses Leiomyosarcomas, Computed Tomography, Histopathology</p><disp-formula id="hanspub.41209-formula22"><graphic xlink:href="//html.hanspub.org/file/60-1571968x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/60-1571968x8_hanspub.png" /> <img src="//html.hanspub.org/file/60-1571968x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>子宫平滑肌肉瘤(Uteruses Leiomyosarcomas, uLMS)起源于间充干细胞，占妇科恶性肿瘤的1.9%及子宫恶性肿瘤的2%~5%。子宫平滑肌瘤是子宫最常见的肿瘤，临床表现为腹痛，出血，不育等。uLMS起源未知，部分起源于平滑肌瘤。现有的研究认为子宫肌瘤和uLMS具有类似的特征，并且子宫肌瘤具有向平滑肌肉瘤转化的潜能 [<xref ref-type="bibr" rid="hanspub.41209-ref1">1</xref>]。uLMS预后生存率较差，据文献统计5年生存率为18.8%至68% [<xref ref-type="bibr" rid="hanspub.41209-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.41209-ref3">3</xref>]。uLMS较少发生淋巴结转移，一项妇科肿瘤学期刊研究对59名临床I期和II期uLMS 妇女进行了手术分期分析，结果显示淋巴结转移的发生率 &lt; 5% [<xref ref-type="bibr" rid="hanspub.41209-ref4">4</xref>]。虽然临床上认为子宫迅速增大提示子宫肌瘤恶变，但是仍存在一定争议。根据美国国立综合癌症网络(National Comprehensive Cancer Network, NCCN)治疗指南，对病理切缘阴性uLMS进行彻底手术切除是基本的治疗方法，能够提高患者生存治疗 [<xref ref-type="bibr" rid="hanspub.41209-ref5">5</xref>]。其他手术方法包括子宫加双侧附件切除术、腹腔镜手术等。腹式全子宫加双附件全切除术是早期疾病的标准手术切除方式，也是主要的治疗方法，术后辅助常规盆腔放疗和化疗可以改善高危患者的局部肿瘤控制，降低复发风险 [<xref ref-type="bibr" rid="hanspub.41209-ref6">6</xref>]。最近研究争议集中在预先诊断为子宫肌瘤患者行肿瘤碎裂术，术后标本显示为uLMS，存在肿瘤播散种植风险 [<xref ref-type="bibr" rid="hanspub.41209-ref7">7</xref>]。因此，对于平滑肌肉瘤的准确认识对于临床治疗方案的选择具有重大的意义 [<xref ref-type="bibr" rid="hanspub.41209-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.41209-ref9">9</xref>]。</p><p>本文通过对14例uLMS的CT征象，肿瘤标志物及病理表现进行分析，并对CT强化程度与Ki67增殖指数的相关性进行分析，提示能作为预测子宫平滑肌瘤恶性转变的标志。</p></sec><sec id="s6"><title>2. 材料与方法</title><sec id="s6_1"><title>2.1. 病人</title><p>收集本院从2012.1至2017.5 uLMS的病例，所有病例均为首次就诊，且最终经手术或穿刺病理证实，并排除术前放化疗、激素治疗、介入治疗、怀孕患者及仅具CT增强检查禁忌症而仅行CT平扫的患者，最终共14例符合入组条件。病人年龄35~71岁，中位年龄50岁。主要的临床症状：出血，子宫迅速增大，腹痛，腹胀和月经紊乱。分析病人的CT表现及增强CT值变化，Ki67增殖指数及肿瘤标志物。</p></sec><sec id="s6_2"><title>2.2. CT扫描及肿瘤标志物分析</title><p>CT扫描的设备分别是64排螺旋CT (SOMATOM Sensation 64, Siemens)及128排螺旋CT (Discovery CT750 HD; GE)。所有病人均接受CT平扫及增强扫描，增强扫描于平扫后注入造影剂56 s后进行。CT扫描参数：5 mm层厚，5 mm层间距，FOV 324~500 mm，矩阵512 &#215; 512，120 kV，220 mAs。</p><p>治疗前对患者进行抽血，血清离心速度3000 r/min持续15分钟，肿瘤标志物CA125，CA199，CEA，AFP，SCC及TESTO测试使用电化学发光(Abbott Laboratories i2000<sup>TM</sup>, Abbott Park, USA)。</p></sec><sec id="s6_3"><title>2.3. 组织病理学检测</title><p>Ki67反映细胞增殖状态，其功能与有丝分裂密切相关，并参与肿瘤细胞的增殖和调控。所有标本经HE染色及免疫组化固定。Ki67评分标准：在&#215;400镜下随机选取10个视野，每个视野计数100个肿瘤细胞，观察细胞的染色强度，计算阳性细胞百分率，按半定量积分法判定表达结果，阳性细胞百分率 &lt; 5%为0分，5%~25%为1分，26%~50%为2分，51%~75%为3分，&gt;75%为4分；细胞无着色为0分，淡黄色为1分，棕黄色为2分，棕褐色为3分。两者评分乘积0~4分为阴性(−)，5分及以上为阳性(+) [<xref ref-type="bibr" rid="hanspub.41209-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.41209-ref11">11</xref>]。</p></sec><sec id="s6_4"><title>2.4. 数据分析</title><p>对患者年龄、种族、绝经情况、目前的症状、治疗方法、分期及生存状态等临床数据进行分析，其中临床分期参考子宫肉瘤2009版FIGO分期系统。CT分析病变的数量、大小、形态、位置、边缘、坏死百分比、平扫及增强CT值，将感兴趣区置于病变的实性成分处，避开坏死、出血及钙化区，不同区域测量三次取平均值，采用均数 &#177; 标准差记录CT值。与邻近子宫肌肉对比，依增强强化程度将其分为三类：明显强化(&gt;50 HU)、中度强化(30~50 HU)及轻度强化(10~30 HU)。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. CT增强值与Ki-67表达的相关性分析</title><p>9例病变实性成分CT呈中至重度强化，5例呈轻度强化，可见明显供血血管，增强呈快进快出表现。实性成分增强强化程度高于邻近正常的肌肉组织，增强呈“花瓣状”强化(详见表1及图1)。9例中至重度强化病例中Ki67阳性组7例，阴性组2例。5例轻度强化病例中Ki67阳性组2例，阴性组3例。</p><p>Ki67阳性组CT强化值为52.49 &#177; 11.22 HU，Ki67阴性组19.03 &#177; 8.12 HU，Ki67阳性组强化程度明显高于Ki67阴性组。采用SPSS 16.0统计软件进行数据分析，组间比较用x<sup>2</sup>检验(p &lt; 0.05)。</p></sec><sec id="s7_2"><title>3.2. 临床数据</title><p>14个病人中汉族11个3个壮族，5个病人已绝经，9个未绝经。大部分患者的临床症状为出血，其它临床表现包括盆腔快速增大的肿物、腹痛、腹胀及月经紊乱。11个患者经手术切除或腹腔镜切除，另有3例患者经细针穿刺病例确诊。FIGO分期I、II、III、IV期分别有7、1、1、5例。5年随访显示，3例由于肿瘤转移或者其它并发症而死亡，10个患者仍活着，1例失访(详见表2)。</p></sec><sec id="s7_3"><title>3.3. 其它CT表现</title><p>肿物最大径1~15.4 cm，其中9/14 (64.3%)肿物直径大于5 cm。11/14 (78.6%)呈卵圆形或圆形，3/14 (21.4%)肿物形态不规则。4例位于子宫前壁，8例位于后壁，1例占据整个子宫，另有1例超出子宫。11/14 (79%)边界不清，3/14 (21.4%)肿物边界清晰。9 (64.3%)例肿物内坏死比例超过50% (详见表1)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> CT characteristics of the leiomyosarcoma patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >患者</th><th align="center" valign="middle" >大小(cm)</th><th align="center" valign="middle" >形态</th><th align="center" valign="middle" >位置</th><th align="center" valign="middle" >边缘</th><th align="center" valign="middle" >坏死比率</th><th align="center" valign="middle" >平扫CT值 Mean &#177; SD</th><th align="center" valign="middle" >增强CT值 Mean &#177; SD</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.6 &#215; 1.0 &#215; 2.5</td><td align="center" valign="middle" >卵圆形</td><td align="center" valign="middle" >宫底前壁</td><td align="center" valign="middle" >边界不清</td><td align="center" valign="middle" >80%</td><td align="center" valign="middle" >61.55 &#177; 7.86</td><td align="center" valign="middle" >72.48 &#177; 11.41</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.8 &#215; 1.0 &#215; 1.7</td><td align="center" valign="middle" >卵圆形</td><td align="center" valign="middle" >宫底前壁</td><td align="center" valign="middle" >边界不清</td><td align="center" valign="middle" >60%</td><td align="center" valign="middle" >60.39 &#177; 7.59</td><td align="center" valign="middle" >86.56 &#177; 10.24</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0.6 &#215; 1.0 &#215; 1.0</td><td align="center" valign="middle" >卵圆形</td><td align="center" valign="middle" >宫底后壁</td><td align="center" valign="middle" >边界不清</td><td align="center" valign="middle" >50%</td><td align="center" valign="middle" >43.75 &#177; 9.03</td><td align="center" valign="middle" >112.24 &#177; 7.81</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >11.8 &#215; 10.0 &#215; 13.6</td><td align="center" valign="middle" >卵圆形</td><td align="center" valign="middle" >宫底及宫体</td><td align="center" valign="middle" >边界不清</td><td align="center" valign="middle" >60%</td><td align="center" valign="middle" >43.75 &#177; 9.54</td><td align="center" valign="middle" >77 &#177; 12.17</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >10.4 &#215; 7.8 &#215; 11.9</td><td align="center" valign="middle" >不规则</td><td align="center" valign="middle" >后壁</td><td align="center" valign="middle" >边界不清</td><td align="center" valign="middle" >80%</td><td align="center" valign="middle" >47.33 &#177; 7.28</td><td align="center" valign="middle" >110.35 &#177; 11.99</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >5.4 &#215; 5.9 &#215; 4.0</td><td align="center" valign="middle" >圆形</td><td align="center" valign="middle" >宫底后壁</td><td align="center" valign="middle" >边界不清</td><td align="center" valign="middle" >40%</td><td align="center" valign="middle" >44.39 &#177; 5.85</td><td align="center" valign="middle" >123.56 &#177; 10.26</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >9.1 &#215; 9.6 &#215; 7.8</td><td align="center" valign="middle" >圆形</td><td align="center" valign="middle" >宫体后壁</td><td align="center" valign="middle" >边界不清</td><td align="center" valign="middle" >70%</td><td align="center" valign="middle" >47.66 &#177; 9.25</td><td align="center" valign="middle" >69.93 &#177; 7.88</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >9.1 &#215; 9.8 &#215; 14.9</td><td align="center" valign="middle" >圆形</td><td align="center" valign="middle" >宫底后壁</td><td align="center" valign="middle" >边界不清</td><td align="center" valign="middle" >20%</td><td align="center" valign="middle" >36.88 &#177; 6.74</td><td align="center" valign="middle" >67.84 &#177; 7.61</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >2.4 &#215; 3.5 &#215; 2.3</td><td align="center" valign="middle" >不规则</td><td align="center" valign="middle" >宫体前壁</td><td align="center" valign="middle" >边界清</td><td align="center" valign="middle" >50%</td><td align="center" valign="middle" >32.35 &#177; 8.65</td><td align="center" valign="middle" >72.27 &#177; 7.11</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >1.6 &#215; 1.8 &#215; 1.7</td><td align="center" valign="middle" >圆形</td><td align="center" valign="middle" >宫体后壁</td><td align="center" valign="middle" >边界清</td><td align="center" valign="middle" >80%</td><td align="center" valign="middle" >34.49 &#177; 12.09</td><td align="center" valign="middle" >49.03 &#177; 13.12</td></tr><tr><td align="center" valign="middle" >11</td><td align="center" valign="middle" >6.6 &#215; 6.4 &#215; 5.9</td><td align="center" valign="middle" >圆形</td><td align="center" valign="middle" >宫体后壁</td><td align="center" valign="middle" >边界清</td><td align="center" valign="middle" >10%</td><td align="center" valign="middle" >55.19 &#177; 7.85</td><td align="center" valign="middle" >135.89 &#177; 15.96</td></tr><tr><td align="center" valign="middle" >12</td><td align="center" valign="middle" >15.4 &#215; 8.6 &#215; 9.7</td><td align="center" valign="middle" >不规则</td><td align="center" valign="middle" >突出子宫</td><td align="center" valign="middle" >边界不清</td><td align="center" valign="middle" >20%</td><td align="center" valign="middle" >39.33 &#177; 5.99</td><td align="center" valign="middle" >73.93 &#177; 6.75</td></tr><tr><td align="center" valign="middle" >13</td><td align="center" valign="middle" >7.2 &#215; 9.5 &#215; 7.7</td><td align="center" valign="middle" >圆形</td><td align="center" valign="middle" >宫体前壁</td><td align="center" valign="middle" >边界不清</td><td align="center" valign="middle" >80%</td><td align="center" valign="middle" >41.93 &#177; 5.07</td><td align="center" valign="middle" >64.4 &#177; 5.53</td></tr><tr><td align="center" valign="middle" >14</td><td align="center" valign="middle" >3.9 &#215; 5.7 &#215; 2.8</td><td align="center" valign="middle" >卵圆形</td><td align="center" valign="middle" >宫体后壁</td><td align="center" valign="middle" >边界不清</td><td align="center" valign="middle" >30%</td><td align="center" valign="middle" >39.23 &#177; 9.27</td><td align="center" valign="middle" >79.9 &#177; 10.97</td></tr></tbody></table></table-wrap><p>表1. uLMS患者CT特征</p><p>图1. 女，57岁，uLMS病例</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Clinical characteristics of the leiomyosarcoma patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >患者</th><th align="center" valign="middle" >年龄</th><th align="center" valign="middle" >种族</th><th align="center" valign="middle" >月经状态</th><th align="center" valign="middle" >症状</th><th align="center" valign="middle" >治疗方式</th><th align="center" valign="middle" >FIGO分期</th><th align="center" valign="middle" >生存状态(月)</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >汉</td><td align="center" valign="middle" >未绝经</td><td align="center" valign="middle" >出血</td><td align="center" valign="middle" >腹腔镜</td><td align="center" valign="middle" >IA</td><td align="center" valign="middle" >存活(2)</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >汉</td><td align="center" valign="middle" >未绝经</td><td align="center" valign="middle" >出血</td><td align="center" valign="middle" >腹腔镜</td><td align="center" valign="middle" >IA</td><td align="center" valign="middle" >存活(21)</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >汉</td><td align="center" valign="middle" >已绝经</td><td align="center" valign="middle" >肿块</td><td align="center" valign="middle" >腹腔镜</td><td align="center" valign="middle" >IB</td><td align="center" valign="middle" >存活(17)</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >57</td><td align="center" valign="middle" >汉</td><td align="center" valign="middle" >已绝经</td><td align="center" valign="middle" >腹胀</td><td align="center" valign="middle" >穿刺</td><td align="center" valign="middle" >IVB</td><td align="center" valign="middle" >死亡(8)</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >46</td><td align="center" valign="middle" >壮</td><td align="center" valign="middle" >未绝经</td><td align="center" valign="middle" >肿块</td><td align="center" valign="middle" >开腹双侧卵巢全切</td><td align="center" valign="middle" >IVB</td><td align="center" valign="middle" >存活(26)</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >48</td><td align="center" valign="middle" >壮</td><td align="center" valign="middle" >未绝经</td><td align="center" valign="middle" >肿块</td><td align="center" valign="middle" >开腹双侧卵巢全切</td><td align="center" valign="middle" >III</td><td align="center" valign="middle" >存活(30)</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >55</td><td align="center" valign="middle" >汉</td><td align="center" valign="middle" >未绝经</td><td align="center" valign="middle" >腹痛</td><td align="center" valign="middle" >穿刺</td><td align="center" valign="middle" >IVB</td><td align="center" valign="middle" >死亡(1)</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >51</td><td align="center" valign="middle" >汉</td><td align="center" valign="middle" >已绝经</td><td align="center" valign="middle" >肿块</td><td align="center" valign="middle" >穿刺</td><td align="center" valign="middle" >IVA</td><td align="center" valign="middle" >死亡(7)</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >71</td><td align="center" valign="middle" >汉</td><td align="center" valign="middle" >已绝经</td><td align="center" valign="middle" >出血</td><td align="center" valign="middle" >腹腔镜&amp;双侧卵巢全切</td><td align="center" valign="middle" >IA</td><td align="center" valign="middle" >存活(39)</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >62</td><td align="center" valign="middle" >汉</td><td align="center" valign="middle" >已绝经</td><td align="center" valign="middle" >出血</td><td align="center" valign="middle" >腹腔镜</td><td align="center" valign="middle" >IA</td><td align="center" valign="middle" >存活(43)</td></tr><tr><td align="center" valign="middle" >11</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >壮</td><td align="center" valign="middle" >未绝经</td><td align="center" valign="middle" >出血</td><td align="center" valign="middle" >腹腔镜</td><td align="center" valign="middle" >IB</td><td align="center" valign="middle" >存活(4)</td></tr><tr><td align="center" valign="middle" >12</td><td align="center" valign="middle" >45</td><td align="center" valign="middle" >汉</td><td align="center" valign="middle" >未绝经</td><td align="center" valign="middle" >出血</td><td align="center" valign="middle" >开腹双侧卵巢全切</td><td align="center" valign="middle" >IIB</td><td align="center" valign="middle" >存活(43)</td></tr><tr><td align="center" valign="middle" >13</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >汉</td><td align="center" valign="middle" >未绝经</td><td align="center" valign="middle" >出血</td><td align="center" valign="middle" >开腹双侧卵巢全切</td><td align="center" valign="middle" >IVB</td><td align="center" valign="middle" >失访(2)</td></tr><tr><td align="center" valign="middle" >14</td><td align="center" valign="middle" >45</td><td align="center" valign="middle" >汉</td><td align="center" valign="middle" >未绝经</td><td align="center" valign="middle" >月经紊乱</td><td align="center" valign="middle" >开腹双侧卵巢全切</td><td align="center" valign="middle" >IB</td><td align="center" valign="middle" >存活(69)</td></tr></tbody></table></table-wrap><p>表2. uLMS患者临床特征</p></sec><sec id="s7_4"><title>3.4. 肿瘤标志物及病理学表现</title><p>71.4%的病例中CA-125升高，其它肿瘤标志物如CA19-9，CEA，AFP，SCC及TESTO几乎正常，所有病例Ki-67染色阳性，大部分病例Desmin及SMA阳性(详见表3)。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Tumor markers arrays and pathologic data of the leiomyosarcoma patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >患者</th><th align="center" valign="middle" >CA125</th><th align="center" valign="middle" >CA199</th><th align="center" valign="middle" >CEA</th><th align="center" valign="middle" >AFP</th><th align="center" valign="middle" >SCC</th><th align="center" valign="middle" >TESTO</th><th align="center" valign="middle" >Ki67</th><th align="center" valign="middle" >Desmin</th><th align="center" valign="middle" >SMA</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >9.3</td><td align="center" valign="middle" >16.5</td><td align="center" valign="middle" >&lt;0.5</td><td align="center" valign="middle" >&lt;1.3</td><td align="center" valign="middle" >0.91</td><td align="center" valign="middle" >92.2*</td><td align="center" valign="middle" >+10%</td><td align="center" valign="middle" >++</td><td align="center" valign="middle" >–</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >21.6</td><td align="center" valign="middle" >23.5</td><td align="center" valign="middle" >1.2</td><td align="center" valign="middle" >4.56</td><td align="center" valign="middle" >23.6</td><td align="center" valign="middle" >26.36</td><td align="center" valign="middle" >+20%</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >–</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >11.7</td><td align="center" valign="middle" >10.23</td><td align="center" valign="middle" >2.2</td><td align="center" valign="middle" >3.32</td><td align="center" valign="middle" >11.86</td><td align="center" valign="middle" >142*</td><td align="center" valign="middle" >+15%</td><td align="center" valign="middle" >++</td><td align="center" valign="middle" >+</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >158.5*</td><td align="center" valign="middle" >30.64</td><td align="center" valign="middle" >0.9</td><td align="center" valign="middle" >5.4</td><td align="center" valign="middle" >0.6</td><td align="center" valign="middle" >47.5</td><td align="center" valign="middle" >+70%</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >+</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >193.3*</td><td align="center" valign="middle" >5.43</td><td align="center" valign="middle" >0.73</td><td align="center" valign="middle" >1.19</td><td align="center" valign="middle" >48.62*</td><td align="center" valign="middle" >0.24</td><td align="center" valign="middle" >+40%</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >–</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >215.3*</td><td align="center" valign="middle" >99.8</td><td align="center" valign="middle" >3.3</td><td align="center" valign="middle" >1.8</td><td align="center" valign="middle" >26.3</td><td align="center" valign="middle" >1.69</td><td align="center" valign="middle" >+60%</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >–</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >142.2*</td><td align="center" valign="middle" >5.4</td><td align="center" valign="middle" >0.71</td><td align="center" valign="middle" >2.82</td><td align="center" valign="middle" >0.24</td><td align="center" valign="middle" >22.65</td><td align="center" valign="middle" >+85%</td><td align="center" valign="middle" >–</td><td align="center" valign="middle" >+</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >53.17*</td><td align="center" valign="middle" >4.35</td><td align="center" valign="middle" >0.72</td><td align="center" valign="middle" >2.37</td><td align="center" valign="middle" >0.71</td><td align="center" valign="middle" >&lt;0.025*</td><td align="center" valign="middle" >+25%</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >+</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >51.88*</td><td align="center" valign="middle" >223.6*</td><td align="center" valign="middle" >3.16</td><td align="center" valign="middle" >2.12</td><td align="center" valign="middle" >0.46</td><td align="center" valign="middle" >34.23</td><td align="center" valign="middle" >+30%</td><td align="center" valign="middle" >++</td><td align="center" valign="middle" >++</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >77.65*</td><td align="center" valign="middle" >26.3</td><td align="center" valign="middle" >2.96</td><td align="center" valign="middle" >2.9</td><td align="center" valign="middle" >1.56</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >+30%</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >++</td></tr><tr><td align="center" valign="middle" >11</td><td align="center" valign="middle" >323.56*</td><td align="center" valign="middle" >57.2</td><td align="center" valign="middle" >2.17</td><td align="center" valign="middle" >2.65</td><td align="center" valign="middle" >0.55</td><td align="center" valign="middle" >45.4</td><td align="center" valign="middle" >+5%</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >+</td></tr><tr><td align="center" valign="middle" >12</td><td align="center" valign="middle" >2341*</td><td align="center" valign="middle" >44.33*</td><td align="center" valign="middle" >0.3</td><td align="center" valign="middle" >1.31</td><td align="center" valign="middle" >1.23</td><td align="center" valign="middle" >0.04*</td><td align="center" valign="middle" >+3~5%</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >+</td></tr><tr><td align="center" valign="middle" >13</td><td align="center" valign="middle" >26.49</td><td align="center" valign="middle" >15.71</td><td align="center" valign="middle" >1.47</td><td align="center" valign="middle" >2.2</td><td align="center" valign="middle" >2.36</td><td align="center" valign="middle" >28.63</td><td align="center" valign="middle" >+50%</td><td align="center" valign="middle" >+</td><td align="center" valign="middle" >+</td></tr><tr><td align="center" valign="middle" >14</td><td align="center" valign="middle" >62.57*</td><td align="center" valign="middle" >17.17</td><td align="center" valign="middle" >1.62</td><td align="center" valign="middle" >2.5</td><td align="center" valign="middle" >0.12</td><td align="center" valign="middle" >0.11</td><td align="center" valign="middle" >+95%</td><td align="center" valign="middle" >–</td><td align="center" valign="middle" >+</td></tr></tbody></table></table-wrap><p>表3. uLMS患者肿瘤标志物及病理学指标</p><p>*异常指标。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>本文通过研究CT值与Ki67增值指数相关性，来预测CT值变化能否反应uLMS恶性潜能。大量研究结果显示 [<xref ref-type="bibr" rid="hanspub.41209-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.41209-ref13">13</xref>]，Ki67与肿瘤良恶性呈正相关，与肿瘤恶性程度亦呈正相关，它是判断肿瘤性质及侵袭力的重要标志，对预测肿瘤预后十分重要 [<xref ref-type="bibr" rid="hanspub.41209-ref14">14</xref>]。恶性肿瘤细胞中Ki67的表达水平越高其临床疗效及预后就越差，Ki67可以用作判断肿瘤侵袭力和预后的标志 [<xref ref-type="bibr" rid="hanspub.41209-ref15">15</xref>]。</p><p>本研究显示Ki67高表达组增强CT值变化明显高于Ki67低表达组，Ki67高表达预示uLMS预后差，也即CT值能反应uLMS的恶性程度。本研究用CT来评估肿瘤的大小、形态、位置、边缘、坏死比例、增强强化程度及分期(肿物侵犯的程度、器官及淋巴结转移情况)。本研究显示79%病例边界不清，所有肿物均可见坏死(64%病例坏死比例超过50%)，71%病例实性成分呈中度及明显强化，并可见供血动脉(血管以幼稚血管为主)，增强呈典型的快进快出。肿物实性成分增强强化程度高于邻近子宫肌肉的强化，增强呈“花瓣状”强化，肿物内坏死成分的比例高于实性成分。我们研究结果显示CT对于uLMS的诊断有一定的帮助 [<xref ref-type="bibr" rid="hanspub.41209-ref2">2</xref>]。</p><p>既往研究显示uLMS高风险因素包括年龄、绝经状态、子宫增大等。本研究中患者年龄 ≥ 50.5岁，部分患者绝经 [<xref ref-type="bibr" rid="hanspub.41209-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.41209-ref17">17</xref>]。由于收集的病例受限，经统计到患者5年生存率为71.4%，估计和收集病例为进展期有关。本组病例无淋巴结转移。</p><p>肿瘤标志物升高能一定程度提示恶性肿瘤或疾病进展，CA125可作为卵巢癌、胃肠道癌、呼吸系统及生殖系统肿瘤的特异性指标 [<xref ref-type="bibr" rid="hanspub.41209-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.41209-ref19">19</xref>]。本研究显示CA125在uLMS病例组值显著升高，但不是特意指标。别的肿瘤学指标如CA19-9、CEA、AFP、SCC及TESTO基本正常。</p><p>本研究局限性：第一样本量太小，第二由于本次研究为回顾性研究，未收集患者超声、MRI图像进行比较影像学征象分析，第三未对uLM进行对比分析。但是本研究通过对uLMS的CT表现、肿瘤标志物及病理分析得出，uLMS CT强化程度及Ki67增值情况可能可以预测其恶性转化过程。CA125升高也能预测uLMS的恶性程度。总之，当患者年龄超过40岁、已绝经、子宫忽然增大、CT上肿物边界不清、中央坏死比率超过50%、可见供血动脉、增强呈“快进快出”及“花瓣样强化”表现，则高度提示uLMS。</p></sec><sec id="s9"><title>基金项目</title><p>广西高校中青年教师基础能力提升项目(编号：2018KY0124)及广西卫计委项目(编号：Z20170445, Z20180643, Z20190799, Z20200784)；广西影像医学临床医学研究中心；广西临床重点专科(医学影像科)；广西医科大学附属肿瘤医院优势培育学科(医学影像学科)。</p></sec><sec id="s10"><title>文章引用</title><p>康 巍,黄向阳,钟武宁. 子宫平滑肌肉瘤恶性潜能预测：CT与临床病理特征相关性研究Prediction of Malignant Potential of Leiomyosarcoma: Correlation between Preoperative CT and Pathological Features[J]. 临床医学进展, 2021, 11(03): 1228-1234. https://doi.org/10.12677/ACM.2021.113177</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41209-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Astolfi, A., Nannini, M., Indio, V., et al. (2020) Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile. Cancers, 12, 2126. &lt;br&gt;https://doi.org/10.3390/cancers12082126</mixed-citation></ref><ref id="hanspub.41209-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Santos, P. and Cunha, T.M. (2015) Uterine Sarcomas: Clinical Presentation and MRI Features. Diagnostic and Interventional Radiology, 21, 4-9. &lt;br&gt;https://doi.org/10.5152/dir.2014.14053</mixed-citation></ref><ref id="hanspub.41209-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Allen, M.M., Douds, J.J., Liang, S.X., Desouki, M.M., Parkash, V. and Fadare, O. (2015) An Immunohistochemical Analysis of Stathmin 1 Expression in Uterine Smooth Muscle Tumors: Differential Expression in Leiomyosarcomas and Leiomyomas. International Journal of Clinical and Experimental Pathology, 8, 2795-2801.</mixed-citation></ref><ref id="hanspub.41209-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Pautier, P., Floquet, A., Chevreau, C., et al. (2015) Trabectedin in Combination with Doxorubicin for First-Line Treatment of Advanced Uterine or Soft-Tissue Leiomyosarcoma (LMS-02): A Non-Randomised, Multicentre, Phase 2 Trial. The Lancet Oncology, 16, 457-464. &lt;br&gt;https://doi.org/10.1016/S1470-2045(15)70070-7</mixed-citation></ref><ref id="hanspub.41209-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Sato, K., Yuasa, N., Fujita, M. and Fukushima, Y. (2014) Clinical Application of Diffusion-Weighted Imaging for Preoperative Differentiation between Uterine Leiomyoma and Leiomyosarcoma. American Journal of Obstetrics and Gynecology, 210, 368.e1-368.e8. &lt;br&gt;https://doi.org/10.1016/j.ajog.2013.12.028</mixed-citation></ref><ref id="hanspub.41209-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Leiser, A.L., Anderson, S.E., Nonaka, D., et al. (2006) Apoptotic and Cell Cycle Regulatory Markers in Uterine Leiomyosarcoma. Gynecologic Oncology, 101, 86-91. &lt;br&gt;https://doi.org/10.1016/j.ygyno.2005.09.055</mixed-citation></ref><ref id="hanspub.41209-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Senol, T., Kahramanoglu, I., Muezzinoglu, B. and Yucesoy, I. (2016) Giant Leiomyosarcoma: A Case Report. International Journal of Surgery Case Reports, 19, 109-111. &lt;br&gt;https://doi.org/10.1016/j.ijscr.2015.12.042</mixed-citation></ref><ref id="hanspub.41209-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">杨晓珍, 龙江, 赵鹏, 高文峰, 张永宏. 肝癌分化程度与肝脏CT强化特点及CD34、p53、GPC3、CK19、Ki-67表达的关系[J]. 癌症进展, 2018(15): 1892-1895.</mixed-citation></ref><ref id="hanspub.41209-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Knudsen, N.I., Wernecke, K.D., Siedentopf, F. and David, M. (2017) Fears and Concerns of Patients with Uterine Fibroids—A Survey of 807 Women. Geburtshilfe und Frauenheilkunde, 77, 976-983.  
&lt;br&gt;https://doi.org/10.1055/s-0043-118132</mixed-citation></ref><ref id="hanspub.41209-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">王景宇, 冬冬, 戴春来, 王淑清, 周丹丹. 胃癌CT征象与组织分化及p53、Ki67表达的相关性[J]. 中国医学科学院学报, 2011(5): 555-559.</mixed-citation></ref><ref id="hanspub.41209-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">梁金晓, 林仲秋. 《FIGO 2018癌症报告》——子宫肉瘤诊治指南解读[J]. 中国实用妇科与产科杂志, 2018, 34(12): 1366-1371.</mixed-citation></ref><ref id="hanspub.41209-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Peters, A., Sadecky, A.M., Winger, D.G., et al. (2017) Characterization and Preoperative Risk Analysis of Leiomyosarcomas at a High-Volume Tertiary Care Center. International Journal of Gynecological Cancer, 27, 1183-1190.  
&lt;br&gt;https://doi.org/10.1097/IGC.0000000000000940</mixed-citation></ref><ref id="hanspub.41209-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Ricci, S., Stone, R.L. and Fader, A.N. (2017) Uterine Leiomyosarcoma: Epidemiology, Contemporary Treatment Strategies and the Impact of Uterine Morcellation. Gynecologic Oncology, 145, 208-216.  
&lt;br&gt;https://doi.org/10.1016/j.ygyno.2017.02.019</mixed-citation></ref><ref id="hanspub.41209-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">左艳, 闫彩平, 邓鹏飞, 管元香. 32例子宫肉瘤的临床特点与诊疗分析[J]. 中国实用医药, 2015, 10(18): 95-96.</mixed-citation></ref><ref id="hanspub.41209-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">朱熠, 石宇, 刘红, 王登凤, 向阳, 张国楠. 《实施腹腔镜下子宫(肌瘤)分碎术的中国专家共识》解读[J]. 肿瘤预防与治疗, 2020, 33(8): 633-637.</mixed-citation></ref><ref id="hanspub.41209-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Dai, H., Liu, J., Liang, L., et al. (2014) Increased Lung Cancer Risk in Patients with Interstitial Lung Disease and Elevated CEA and CA125 Serum Tumour Markers. Respirology, 19, 707-713. &lt;br&gt;https://doi.org/10.1111/resp.12317</mixed-citation></ref><ref id="hanspub.41209-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Ahmadi, H., Djaladat, H., Cai, J., Miranda, G. and Daneshmand, S. (2014) Precystectomy Serum Levels of Carbohydrate Antigen 19-9, Carbohydrate Antigen 125, and Carcinoembryonic Antigen: Prognostic Value in Invasive Urothelial Carcinoma of the Bladder. Urologic Oncology, 32, 648-656. &lt;br&gt;https://doi.org/10.1016/j.urolonc.2014.01.019</mixed-citation></ref><ref id="hanspub.41209-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">谢洁林, 田晓梅, 韩志刚, 张国福. 子宫肉瘤的MRI表现与临床病理分析[J]. 肿瘤影像学, 2014, 23(2): 95-98.</mixed-citation></ref><ref id="hanspub.41209-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Juang, C.M., Yen, M.S., Horng, H.C., Twu, N.F., Yu, H.C. and Hsu, W.L. (2006) Potential Role of Preoperative Serum CA125 for the Differential Diagnosis between Uterine Leiomyoma and Uterine Leiomyosarcoma. European Journal of Gynaecological Oncology, 27, 370-374.</mixed-citation></ref></ref-list></back></article>